NASDAQ
Calliditas Therapeutics Ab (CLTEF) has a price/sales ratio of 34125.55x as of Friday, May 22, 2026. This represents a 1626.96% increase compared to its 12-month average of 1976.05x. The price-to-sales ratio evaluates a company's stock price relative to its revenue, useful for valuing companies with little or no earnings.
No price data available for this timeframe.